NYSE: TMOThermo Fisher Scientific Inc Stock
$576.17-11.59 (-1.97%)
Updated Feb 6, 2023
TMO Price
$576.17
Fair Value Price
N/A
Market Cap
$225.97B
52 Week Low
$475.77
52 Week High
$618.36
P/E
32.12x
P/B
5.19x
P/S
4.5x
PEG
1.12x
Dividend Yield
0.21%
Revenue
$44.17B
Earnings
$7.03B
Gross Margin
44.4%
Operating Margin
18.98%
Profit Margin
15.9%
Debt to Equity
1.08
Operating Cash Flow
$8B
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TMO Overview
Thermo Fisher Scientific Incorporated offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. Its products and services are sold through a direct sales force, customer-service professionals, e-commerce, third-party distributors, and catalogs. It has an alliance with the University of California. Thermo Fisher was incorporated in 1956 and is based in Waltham, MA.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TMO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMO ($576.17) is trading above its intrinsic value of $304.14, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMO is poor value based on its earnings relative to its share price (32.12x), compared to the US market average (14.99x)
P/E vs Market Valuation
TMO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more TMO due diligence checks available for Premium users.
Be the first to know about important TMO news, forecast changes, insider trades & much more!
TMO News
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
32.12x
Industry
37.26x
Market
14.99x
TMO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TMO is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.19x
Industry
4.46x
TMO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
TMO's financial health
Profit margin
Revenue
$10.7B
Net Income
$1.5B
Profit Margin
14%
TMO's Earnings (EBIT) of $8.38B... subscribe to Premium to read more.
Interest Coverage Financials
TMO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$90.5B
Liabilities
$46.9B
Debt to equity
1.08
TMO's short-term assets ($19.30B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMO's long-term liabilities ($35.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.9B
Investing
-$545.0M
Financing
-$151.0M
TMO's operating cash flow ($8.12B)... subscribe to Premium to read more.
Debt Coverage Financials
TMO vs Diagnostic & Research Stocks
Thermo Fisher Scientific Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.